Recordati Industria Chimica e Farmaceutica SPA (IT:REC) has released an update.
Recordati has successfully acquired global rights to Enjaymo®, a groundbreaking treatment for cold agglutinin disease, from Sanofi. The acquisition is expected to boost revenue significantly, with Enjaymo® projected to generate over 150 million euros in 2025. This strategic addition strengthens Recordati’s rare diseases portfolio and promises strong financial returns.
For further insights into IT:REC stock, check out TipRanks’ Stock Analysis page.